Ambrx Biopharma, Inc.·4

Dec 11, 5:15 PM ET

O'Connor Daniel J. 4

4 · Ambrx Biopharma, Inc. · Filed Dec 11, 2023

Insider Transaction Report

Form 4
Period: 2023-12-11
O'Connor Daniel
DirectorPresident and CEO
Transactions
  • Award

    Common Stock

    2023-12-11+750,0001,363,332 total
Footnotes (2)
  • [F1]Represents Restricted Stock Units ("RSUs") payable in common stock of the Issuer granted to the Reporting Person on December 11, 2023 (the "Grant Date"). The RSUs were granted in connection with the completion of the year-end review process and will be issued pursuant to the Company's Amended and Restated 2021 Equity Incentive Plan. The award represents an aggregate of the Reporting Person's year-end and make-whole awards based on market data for similarly situated officers at peer companies.
  • [F2]The RSUs will vest over thirty-six (36) months as follows: (i) one-sixth (1/6) of the RSUs will vest on the six (6)-month anniversary of the Grant Date, and (ii) one-twelfth (1/12) of the RSUs will vest on a quarterly basis thereafter.

Documents

1 file
  • 4
    ownership.xmlPrimary

    4